SeaStar Medical已正式完成美国食品药品监督管理局（FDA）针对Quelimmune儿科急性肾损伤安全性监测登记项目的患者入组要求。这一里程碑标志着公司在推进该治疗方案的临床评估与安全监测方面取得重要进展，为后续研究及潜在监管审批奠定基础。
SeaStar Medical已正式完成美国食品药品监督管理局（FDA）针对Quelimmune儿科急性肾损伤安全性监测登记项目的患者入组要求。这一里程碑标志着公司在推进该治疗方案的临床评估与安全监测方面取得重要进展，为后续研究及潜在监管审批奠定基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.